Bicycle Therapeutics to Participate in Upcoming Investor Conferences
June 03 2024 - 7:00AM
Business Wire
Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical
company pioneering a new and differentiated class of therapeutics
based on its proprietary bicyclic peptide (Bicycle®) technology,
today announced that management will participate in the following
investor conferences in June:
- Jefferies Global Healthcare Conference on Wednesday, June 5,
2024; fireside chat at 8:30 a.m. ET
- Goldman Sachs 45th Annual Global Healthcare Conference on
Monday, June 10, 2024; fireside chat at 1:20 p.m. ET
- TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on
Monday, June 17, 2024; fireside chat at 3:00 p.m. ET
Live webcasts of the fireside chats will be accessible in the
Investor section of the Company’s website at
www.bicycletherapeutics.com. Archived replays of the webcasts will
be available following the fireside chat dates.
About Bicycle Therapeutics Bicycle Therapeutics is a
clinical-stage pharmaceutical company developing a novel class of
medicines, referred to as Bicycle® molecules, for diseases that are
underserved by existing therapeutics. Bicycle molecules are fully
synthetic short peptides constrained with small molecule scaffolds
to form two loops that stabilize their structural geometry. This
constraint facilitates target binding with high affinity and
selectivity, making Bicycle molecules attractive candidates for
drug development. The company is evaluating zelenectide pevedotin,
previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting
Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule
targeting EphA2, a historically undruggable target; and BT7480, a
Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®)
targeting Nectin-4 and agonizing CD137, in company-sponsored
clinical trials. Additionally, the company is developing Bicycle®
Radio Conjugates (BRC™) for radiopharmaceutical use and, through
various partnerships, is exploring the use of Bicycle® technology
to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in Cambridge, UK, with
many key functions and members of its leadership team located in
Cambridge, Mass. For more information, visit
bicycletherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240603383416/en/
Investors: Stephanie Yao SVP, Investor Relations and
Corporate Communications ir@bicycletx.com 857-523-8544
Media: Deborah Elson Argot Partners media@bicycletx.com
212-600-1902
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart
From Sep 2023 to Sep 2024